Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M. N., Leonard, J. P., Fehrenbacher, L., Lister, T., Horner, T. J., Williams, V. C., Lin, T. S., Vleisides, C., Knox, S. J., Wahl, R. L., Vose, J. M. AMER SOC HEMATOLOGY. 2010: 1615

View details for Web of Science ID 000289662204380